We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+19.03%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$4.08B
AUM Growth
+$976M
Cap. Flow
+$545M
Cap. Flow %
13.34%
Top 10 Hldgs %
75.07%
Holding
69
New
11
Increased
11
Reduced
6
Closed
16

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$97.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$85.3M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$61.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$49.6M
5
RVMD icon
Revolution Medicines
RVMD
+$45.3M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$45.3M
2
KYMR icon
Kymera Therapeutics
KYMR
+$23.6M
3
ACET icon
Adicet Bio
ACET
+$20.5M
4
DYN icon
Dyne Therapeutics
DYN
+$18M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRON
51
DELISTED
Kronos Bio
KRON
$562K 0.01%
326,780
– –
CMAXW
52
DELISTED
CareMax, Inc. Warrant
CMAXW
$311K 0.01%
100,000
– –
SRZNW icon
53
Surrozen Inc Warrant
SRZNW
$49.5K
$36.7K ﹤0.01%
66,665
– –
ACET icon
54
Adicet Bio
ACET
$72.8M
– –
-222,544
Closed -$20.5M
ARQT icon
55
Arcutis Biotherapeutics
ARQT
$3.42B
– –
-415,322
Closed -$4.57M
BDTX icon
56
Black Diamond Therapeutics
BDTX
$101M
– –
-1,191,094
Closed -$2.25M
BEAM icon
57
Beam Therapeutics
BEAM
$2.58B
– –
-198,591
Closed -$6.08M
CGEM icon
58
Cullinan Oncology
CGEM
$1.05B
– –
-246,410
Closed -$2.52M
ERAS icon
59
Erasca
ERAS
$6.63B
– –
-678,441
Closed -$2.04M
ITOS
60
DELISTED
iTeos Therapeutics
ITOS
– –
-1,300
Closed -$17.7K
KYMR icon
61
Kymera Therapeutics
KYMR
$9.1B
– –
-796,093
Closed -$23.6M
MGNX icon
62
MacroGenics
MGNX
$235M
– –
-619,192
Closed -$4.44M
RNAC icon
63
Cartesian Therapeutics
RNAC
$232M
– –
-6,667
Closed -$278K
CYT
64
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
– –
-43,823
Closed -$79.8K
GRCL
65
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-798,948
Closed -$1.49M
SURF
66
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-3,082,959
Closed -$2.15M
KDNY
67
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-445,550
Closed -$10.3M
EUCRW
68
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
– –
-66,666
Closed -$676K
EUCR
69
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
– –
-200,000
Closed -$2.03M
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q2 2023 Portfolio in Review

As of Q2 2023, EcoR1 Capital held 69 positions worth $4.08B, up 31% from $3.11B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

EcoR1 Capital deployed $545M of net new capital in Q2 2023, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Blueprint Medicines: 1,798,300 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $45.3M trimmed.

  • EcoR1 Capital's largest Q2 2023 buy was Blueprint Medicines: 1,798,300 shares worth $114M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q2 2023, an estimated $85.3M increase.
  • EcoR1 Capital's biggest Q2 2023 reduction was Janux Therapeutics, cutting an estimated $45.3M.
  • EcoR1 Capital fully exited Kymera Therapeutics in Q2 2023, selling an estimated $23.6M.
  • EcoR1 Capital's ten largest holdings make up 75% of its $4.08B portfolio in Q2 2023.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q2 2023.
  • EcoR1 Capital's portfolio value rose 31% quarter-over-quarter to $4.08B.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.